EA202190696A1 - Новые гидрохлоридные солевые формы сульфонамидного структурированного ингибитора киназы - Google Patents

Новые гидрохлоридные солевые формы сульфонамидного структурированного ингибитора киназы

Info

Publication number
EA202190696A1
EA202190696A1 EA202190696A EA202190696A EA202190696A1 EA 202190696 A1 EA202190696 A1 EA 202190696A1 EA 202190696 A EA202190696 A EA 202190696A EA 202190696 A EA202190696 A EA 202190696A EA 202190696 A1 EA202190696 A1 EA 202190696A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrochloride salt
salt forms
sulfonamide
structured
kinase inhibitor
Prior art date
Application number
EA202190696A
Other languages
English (en)
Inventor
Дэвид Йонайтис
Оскари Карьялайнен
Original Assignee
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Орион Корпорейшн filed Critical Орион Корпорейшн
Publication of EA202190696A1 publication Critical patent/EA202190696A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/04—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новым гидрохлоридным солевым формам N-(2',4'-дифтор-5-(5-(1-метил-1H-пиразол-4-ил)-1H-бензо[d]имидазол-1-ил)-[1,1'-бифенил]-3-ил)циклопропансульфонамида (I). Соединение формулы (I) является селективным ингибитором семейств киназ FGFR/VEGFR и может использоваться при лечении рака.
EA202190696A 2018-09-06 2019-09-05 Новые гидрохлоридные солевые формы сульфонамидного структурированного ингибитора киназы EA202190696A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20185743 2018-09-06
PCT/FI2019/050629 WO2020049217A1 (en) 2018-09-06 2019-09-05 Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor

Publications (1)

Publication Number Publication Date
EA202190696A1 true EA202190696A1 (ru) 2021-06-16

Family

ID=67982092

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190696A EA202190696A1 (ru) 2018-09-06 2019-09-05 Новые гидрохлоридные солевые формы сульфонамидного структурированного ингибитора киназы

Country Status (12)

Country Link
US (1) US11866420B2 (ru)
EP (1) EP3846906A1 (ru)
JP (1) JP7528060B2 (ru)
KR (1) KR20210057759A (ru)
CN (1) CN112805065B (ru)
AU (1) AU2019334693A1 (ru)
CA (1) CA3111040A1 (ru)
EA (1) EA202190696A1 (ru)
MA (1) MA53546A (ru)
MX (1) MX2021002524A (ru)
SG (1) SG11202102110PA (ru)
WO (1) WO2020049217A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018172616A1 (en) * 2017-03-23 2018-09-27 Orion Corporation Process for the preparation of a sulfonamide structured kinase inhibitor
MX2022011058A (es) * 2020-03-05 2022-12-13 Aurigene Discovery Tech Ltd Composiciones farmaceuticas de un inhibidor de cinasa.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111382C2 (uk) 2011-10-10 2016-04-25 Оріон Корпорейшн Інгібітори протеїнкінази
WO2018172616A1 (en) * 2017-03-23 2018-09-27 Orion Corporation Process for the preparation of a sulfonamide structured kinase inhibitor
WO2020135878A1 (zh) * 2018-12-29 2020-07-02 南京明德新药研发有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
CN113993867B (zh) * 2019-06-14 2023-10-24 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的并环类化合物

Also Published As

Publication number Publication date
CN112805065A (zh) 2021-05-14
MX2021002524A (es) 2021-04-28
JP2022501328A (ja) 2022-01-06
SG11202102110PA (en) 2021-04-29
CN112805065B (zh) 2024-07-05
MA53546A (fr) 2021-12-15
AU2019334693A1 (en) 2021-05-13
US20210332028A1 (en) 2021-10-28
US11866420B2 (en) 2024-01-09
WO2020049217A1 (en) 2020-03-12
EP3846906A1 (en) 2021-07-14
CA3111040A1 (en) 2020-03-12
JP7528060B2 (ja) 2024-08-05
KR20210057759A (ko) 2021-05-21

Similar Documents

Publication Publication Date Title
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
EA201070480A1 (ru) Ингибиторы с-fms киназы
EA202090256A1 (ru) 5-членные и бициклические гетероциклические амиды в качестве ингибиторов rock
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
EA201000113A1 (ru) Пиразольные соединения
NO20070606L (no) Inhibitorer av IAP
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
EA201171213A1 (ru) Ингибитор р38 мар киназы
EA201591913A1 (ru) Ингибиторы протеинкиназы
EA202190696A1 (ru) Новые гидрохлоридные солевые формы сульфонамидного структурированного ингибитора киназы
EA201990902A1 (ru) Ингибиторы тирозинкиназы брутона
EA200802329A1 (ru) Производные триазола ii
PE20050229A1 (es) Derivados de etinilprolina
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
TW200635585A (en) Monocyclic substituted methanones
AR038914A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion para fabricar un medicamento
EA201000848A1 (ru) Ингибиторы протеинкиназы и их применение
PE20110830A1 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas
DE602005025332D1 (de) 4-ä2-(cycloalkylamino)pyrimidin-4-ylü-(phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten
BR112013004624A2 (pt) "derivados de furopiridina"
AR066972A1 (es) Derivados azapeptidicos